Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Unknown × Spironolactone × Clear all

Phase

Phase NA 1 Phase EARLY_PHASE1 1 Phase 4 1 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 1 Critical Illness 1 Acute Kidney Injury 1

Interventions

Docetaxel 16 Cisplatin 16 Capecitabine 15 Drug Therapy 14 Cyclophosphamide 13 Oxaliplatin 12 Fluorouracil 12 Radiotherapy 11 Paclitaxel 9 apatinib 8 Epirubicin 7 Doxorubicin 7 Decitabine 7 sintilimab 6 Methotrexate 6 Gemcitabine 6 Carboplatin 6 Busulfan 6 anlotinib 5 XELOX 5 Pemetrexed 5 Leucovorin 5 Etoposide 5 Dexamethasone 5 lenvatinib 4 camrelizumab 4 Surgical Procedures, Operative 4 Radiosurgery 4 Neoadjuvant Therapy 4 Cytarabine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02531412 2017-01-04

SPIROCAN

Instituto Nacional de Cancerologia de Mexico

Phase 2/3 Unknown

Neoplasms, Critical Illness, Acute Kidney Injury

Data powered by HemOnc (CC BY 4.0) Colophon ⚡